Videos

Key opinion leaders give insight on the presentation of sickle cell disease, also highlighting acute vs chronic complications of the disease.

Joe Avelino, RN, BSN, MHSA, CPHQ, reviews the benefits of using long-acting injectables (LAIs) and Henry Nasrallah, MD, reviews his techniques for getting patients to accept LAIs and continue with them. 

Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.  

A dermatologist discusses alternative and complementary options for the treatment of atopic dermatitis.

Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.

Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss the importance of an integrative approach to care for the management of atopic dermatitis.

New data show reduced risk of mortality, and clinical savings upward of $100,000, are linked to sometimes inaccessible substance use disorder therapies.

The pandemic forced practices to consider more virtual screening and care. A dermatologist shares perspective on what's been working as telemedicine practice.

Using the ACC Expert Consensus Decision Pathway documents for the optimization of heart failure treatment and managing the increasing complexity of the disease.

A look into the role of heart failure treatment in health care and the overall provision of optimal medical therapy.

Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges. 

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

Experts discuss the prevalence and burden of sickle cell disease.

Wally Smith, MD, and Abdullah Kutlar, MD provide an overview of sickle cell disease and its pathophysiology.

Henry Nasrallah, MD, recalls the history behind long-acting injectables in patients with schizophrenia.

A panel of experts in psychiatric treatment review the burden schizophrenia has on the health care system.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, shares ways to improve naloxone accessibility, and Theresa Mallick-Searle, MS, RN-BC, ANP-BC, discusses stigmatization.

Experts weigh in on protocols, policies, and programs that influence patient safety and address when a conversation should ensue with patients about naloxone.

Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.

Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.

Elizabeth Swanson, MD, leads the discussion on emerging data on comorbid conditions associated with atopic dermatitis and management in the clinical setting.

An expert offers his perspective on the investigative SLP receptor modulator for atopic dermatitis.

The role of early aggressive treatment in preventing progression of heart failures and the importance of understanding the root cause of disease.

Javed Butler, MD, MPH, MBA, discusses the staging and difficulties associated with diagnosing heart failure.